AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018
SAN DIEGO--(BUSINESS WIRE)--Sep 24, 2018--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that clinical case series data from the company’s expanded access program for its two investigational bacteriophage therapeutics, AB-SA01 and AB-PA01, will be presented in an oral abstract session “Novel Therapies for Superbugs” at IDWeek 2018, being held October 3-7 in San Francisco.
Details of the oral abstract session are as follows:
Title: Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data Oral Abstract Session: Novel Therapies for Superbugs Abstract number: 1642 Date/Time: Friday, October 5, 2018, 2:45 p.m. PDT Location: Room S 158 Presenter: Prof. Jonathan Iredell, Critical Infectious Diseases, Westmead Hospital and Critical Infection, Westmead Institute for Medical Research, Sydney, Australia
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead clinical stage product candidates, AB-SA01 and AB-PA01, target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms (a common bacterial defense mechanism against antibiotics), are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information visit www.ampliphibio.com.
Bacteriophages, or more simply “phages,” are the natural predators of bacteria and are thought to be the most abundant life form on earth. Phages have evolved an incredible diversity of strains that typically prey upon just a few closely related strains or species of bacteria, enabling phage therapies to precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic-resistant or not, and even when they have formed protective biofilms.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005281/en/
CONTACT: At the Company:
Matthew Dansey, 858-800-4869
Robert H. Uhl, 858-356-5932
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: AmpliPhi Biosciences Corporation
Copyright Business Wire 2018.
PUB: 09/24/2018 06:50 AM/DISC: 09/24/2018 06:50 AM